

October 4, 2021

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Disclosure u/r 29 (2) of SEBI (SAST) Regulations, 2011.

I, Penaka Suneela Rani, belonging to the Promoter group of Aurobindo Pharma Limited, pursuant to the acquisition of shares (inter-se transfer) through gift from my relative, Mrs. Penaka Neha Reddy (Promoter group), enclose herewith the disclosure required under regulation 29(2) of SEBI (SAST) Regulations, 2011. It may also be noted that the said transaction will not affect the overall holding of the Promoter group of Aurobindo Pharma Limited.

Please take the information on record.

This disclosure is also being forwarded to the Company.

Thanking you,

Yours faithfully,

Penaka Suneela Rani

PENAKA SUNEELA RANI
Plot No.415, Road No.18,
Opp.Ramalayam Temple,
Jubilee Hills, Shaikpet,
Hyderabad 500033

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	AUROBINDO PHARMA LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	MRS. PENAKA SUNEELA RANI		
Whether the acquirer belongs to Promoter/Promoter group	Yes – Promoter group.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The National Stock Exchange of India Limited BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights	Nil	N.A	N.A
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	N.A	N.A
c) Voting rights (VR) otherwise than by shares	Nil	N.A	N.A
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	Nil	N.A	N.A
e) Total (a+b+c+d)	Nil	N.A	N.A
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	1,30,000	0.02	0.02
b) VRs acquired /sold otherwise than by shares	Nil	N.A	N.A
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	Nil	N.A	N.A
d) Shares encumbered / invoked/released by the acquirer	Nil	N.A	N.A
e) Total (a+b+c+/-d)	1,30,000	0.02	0.02

For T. J. Santanu Reddy

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	1,30,000	0.02	0.02
b) Shares encumbered with the acquirer	Nil	N.A	N.A
c) VRs otherwise than by shares	Nil	N.A	N.A
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	N.A	N.A
e) Total (a+b+c+d)	1,30,000	0.02	0.02
Mode of acquisition /sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Inter-se off-market acquisition from immediate relative as gift.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	30.09.2021		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs.58,59,38,609 (58,59,38,609 equity shares of Re.1/- each)		
Equity share capital/ total voting capital of the TC after the said acquisition /sale	Rs.58,59,38,609 (58,59,38,609 equity shares of Re.1/- each)		
Total diluted share/voting capital of the TC after the said acquisition	N.A		

Note: Prior to the acquisition of aforesaid shares, Mrs. Penaka Suneela Rani was not holding directly any shares in Aurobindo Pharma Limited (the Company). However, Mrs. Penaka Suneela Rani is indirectly holding 36.50% in the Company as ultimate beneficial owner of the shares held in the registered names of 1) RPR Sons Advisors Private Limited and P Suneela Rani (Jointly Holding), 2) Axis Clinicals Limited, RPR Sons Advisors Private Limited and Trident Chemphar Limited (Jointly holding), 3) Axis Clinicals Limited and 4) Trident Chemphar Limited.

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (LODR) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For T. S. Sankar Reddy

Signature of the acquirer / seller / Authorised Signatory

Place: Hyderabad

Date: 04.10.2021
